448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts. (23rd October 2018) - Penson, R T; Drew, Y; de Jonge, M J A; Hong, S-H; Park, Y H; Wolfer, A; Brown, J; Ferguson, M; Gore, M E; Alvarez, R H; Kaufman, B; Gresty, C; et al.